AIM ImmunoTech Inc. (AIM) is a publicly traded company in the Healthcare — Biotechnology industry listed on AMEX. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Analysis Summary
AIM ImmunoTech Inc. reported revenue of $88000 in the most recent fiscal year, growing at a 5-year CAGR of -11.6%.
Trailing-twelve-month margins: gross margin -125.3%, operating margin -116.4%, net margin -150.2%.
At the current price of $0.21, AIM has negative trailing earnings (P/E not meaningful) and an ROE of 9.53%. Market capitalisation stands at $1M.
Balance sheet quality for AIM: current ratio of 0.5, net debt of $3.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.21 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 952.76% |
| Return on Invested Capital | -94.78% |
| Return on Assets | -112.09% |
| Gross Margin | -125.26% |
| Operating Margin | -11637.89% |
| Net Margin | -15021.05% |
Financial Health
| Debt / Equity | 0.51 |
| Current Ratio | 2.11 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | 0.46 | 9.5% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -9.36% |
| 3 months | -44.20% |
| Year-to-date | -81.24% |
| 1 year | -91.17% |
| 3 years | -99.63% |
| 5 years | -99.89% |
52-Week Range
| 52-week High | $2.80 |
| 52-week Low | $0.19 |
| Avg Volume (90d) | 22.1M |
Related companies: CANF · ENSC · KALA · KTTA · OGEN · QNRX · SNGX
Explore sector: Healthcare · Biotechnology
More sections of AIM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks